- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT06694701
Trattamento con emapalumab per un beneficio clinico atteso nella sepsi determinata dall'endotipo dell'interferone-gamma (studio EMBRACE) (EMBRACE)
EMBRACE is a double-blind, randomized, placebo-controlled, phase IIa study that will be conducted in multiple Intensive Care Units (ICUs) and departments of Internal Medicine across Greece. It aims to investigate if treatment with emapalumab, a monoclonal antibody which blocks IFNγ, may improve the outcome of patients with sepsis driven by the IDS (endotype of IFNγ-driven sepsis) endotype. EMBRACE also aims to identify the best dosing regimen of emapalumab for the management of IDS.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
The EMBRACE trial aims to generate proof-of-concept if treatment with emapalumab, a monoclonal antibody which blocks IFNγ signaling, may improve the outcome of patients with sepsis driven by the IDS endotype. In EMBRACE, two different dose regimens of emapalumab are administered in order to: a) investigate which dose regimen may provide most of efficacy in the decrease of SOFA score, a new endpoint for sepsis suggested already by others; b) investigate which dose regimen better attains the pharmacodynamic goal of emapalumab defined as the decrease of blood CXCL9; and c) compare the efficacy of the two dose regimens with placebo treated patients.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 2
Contatti e Sedi
Luoghi di studio
-
-
-
Alexandroupoli, Grecia
- Intensive Care Unit, Alexandroupolis University General Hospital
-
Athens, Grecia
- 4th Department of Internal Medicine, ATTIKON University General Hospital
-
Athens, Grecia
- Intensive Care Unit, Korgialeneio-Benakeio HRC Athens General Hospital
-
Athens, Grecia
- 3rd University Department of Internal Medicine, Sotiria Chest Diseases Athens General Hospital
-
Athens, Grecia
- Intensive Care Unit I, KAT Attica General Hospital
-
Athens, Grecia
- Intensive Care Unit of 1st University Department Respiratory Medicine, Sotiria Chest Diseases Athens General Hospital
-
Athens, Grecia
- Intensive Care Unit of Center for Respiratory Failure, Sotiria Chest Diseases Athens General Hospital
-
Athens, Grecia
- Intensive Care Unit, Asklipieio Voulas General Hospital
-
Athens, Grecia
- Intensive Care Unit, Ippokrateio Athens General Hospital
-
Athens, Grecia
- Intensive Care Unit, Laiko Athens General Hospital
-
Athens, Grecia
- New Multivalent Intensive Care Unit, Sotiria Chest Diseases Athens General Hospital
-
Athens, Grecia
- Ηigh Dependency Unit of Department of Clinical Therapeutics, Alexandra Athens General Hospital
-
Pátrai, Grecia
- Intensive Care Unit, Patras University General Hospital
-
Thessaloniki, Grecia
- 1st Intensive Care Unit, G. Papanikolaou Thessaloniki General Hospital
-
Thessaloniki, Grecia
- Department of Anesthesiology and Intensive Care, AHEPA Thessaloniki University General Hospital
-
Thessaloniki, Grecia
- Intensive Care Unit, 424 General Military Training Hospital
-
Thessaloniki, Grecia
- Intensive Care Unit, Aghios Dimitrios Thessaloniki General Hospital
-
Thessaloniki, Grecia
- Intensive Care Unit, G. Gennimatas Thessaloniki General Hospital
-
Thessaloniki, Grecia
- Intensive Care Unit, Ippokrateio Thessaloniki General Hospital
-
Thessaloniki, Grecia
- Intensive Care Unit, Papageorgiou Thessaloniki General Hospital
-
Thessaloniki, Grecia
- Intensive Care Unit, Theageneio Thessaloniki Cancer Hospital
-
-
Attica
-
Elefsina, Attica, Grecia
- 1st Department of Internal Medicine, Thriasio Elefsis General Hospital
-
Kifissia, Attica, Grecia
- Clinic of Intensive Care and Pulmonary Diseases, Aghioi Anargyroi Kifissia General Oncologic Hospital
-
-
Crete
-
Heraklion, Crete, Grecia
- Intensive Care Unit, University General Hospital of Heraklion
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Provide written informed consent
- Adults (≥18 years) of male or female sex
- Diagnosis of community-acquired pneumonia (CAP), hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), intrabdominal infection (IAI), acute pyelonephritis (AP), primary bloodstream infection (BSI) and viral respiratory infections.
- Sepsis defined by the Sepsis-3 definitions. This is defined as any new infection which is accompanied by an increase of the total baseline SOFA score by at least 2 points. The total baseline SOFA score is calculated by the medical comorbidities and by the evaluation of clinical variables before the sepsis episode in the case of hospital-acquired sepsis. In the case of patients with unknown baseline SOFA score, sepsis is defined as any new infection accompanied by total SOFA score 2 or more.
- Willingness to use effective contraceptive methods during the period from the start of the study drug to 6 months after the administration of the last dose of the study drug, in patients of reproductive age.
- Serological documentation of IDS defined as detectable blood IFNγ and CXCL9 more than 2,200 pg/ml. IFNγ and CXCL9 are measured in the central study lab by an enzyme immunosorbent assay.
- Absence of sepsis-induced immunoparalysis (SII). This is defined as ≥8000 of HLA-DR receptors on CD45/CD14-monocytes measured by flow-cytometry in the central lab using the BD™ fluorescence assay9.
Exclusion Criteria:
- Body weight more than 104 kg
- Intake of any other biological during the last 30 days prior screening except for the intake of anakinra or tocilizumab for patients with active infection by SARS-CoV-2
- Intake of any Janus kinase inhibitors during the last 30 days prior screening except for the intake of baricitinib for patients with active infection by SARS-CoV-2
- Known active infection by Mycobacterium tuberculosis or other mycobacteria. These patients may be enrolled in the trial if treatment against infection by Mycobacterium tuberculosis or other mycobacteria has been initiated
- Known active infection by VZV (varicella zoster virus) or by Histoplasma capsulatum or by Leishmania spp. These patients may be enrolled in the trial if treatment against infection by VZV or Histoplasma capsulatum has been initiated
- Known active infection by the hepatitis B virus, by the hepatitis C virus and by cytomegalovirus
- Vaccination the last 12 weeks before screening with BCG vaccine
- Vaccination with any live or attenuated live vaccine (other than BCG) the last 12 weeks before screening
- Known allergy or hypersensitivity reactions to emapalumab
- Patients living with the human immunodeficiency virus (HIV)
- Patients with stage IV solid or hematologic malignancy
- Patients with neutropenia (less than 1,000 neutrophils/mm3)
- Patients transplanted for solid organ or stem cells
- Pregnancy or lactation
- Participation in any other interventional trial the last 28 days prior to day 1
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Triplicare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Comparatore placebo: Placebo
Standard-of-care (SoC) treatment and placebo drug. |
250ml of 0.9% sodium chloride. The drug is administered on day 0 and repeated dosing is provisioned for days 3, 6, 9, 12, 15, 19, 23 and 27 provided that the stopping rule does not apply |
|
Comparatore attivo: Emapalumab Group 1
SoC treatment and a low dose of emapalumab. |
The drug is administered at a dose of 6mg/kg of body weight on day 0 and repeated dosing of 3mg/kg of body weight is provisioned for days 3, 6, 9, 12, 15, 19, 23 and 27 provided that the stopping rule does not apply.
Altri nomi:
The drug is administered at a dose of 6mg/kg of body weight on day 0, 6mg/kg of body weight on day 3, 6mg/kg of body weight on day 6 and repeated dosing of 3mg/kg of body weight is provisioned for days 9, 12, 15, 19, 23 and 27 provided that the stopping rule does not apply.
Altri nomi:
|
|
Comparatore attivo: Emapalumab Group 2
SoC treatment and a high dose of emapalumab. |
The drug is administered at a dose of 6mg/kg of body weight on day 0 and repeated dosing of 3mg/kg of body weight is provisioned for days 3, 6, 9, 12, 15, 19, 23 and 27 provided that the stopping rule does not apply.
Altri nomi:
The drug is administered at a dose of 6mg/kg of body weight on day 0, 6mg/kg of body weight on day 3, 6mg/kg of body weight on day 6 and repeated dosing of 3mg/kg of body weight is provisioned for days 9, 12, 15, 19, 23 and 27 provided that the stopping rule does not apply.
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Decrease of SOFA score by the end-of-treatment
Lasso di tempo: From enrollment to the end of treatment of the study drug for each of the study participants, ranging from 2 to 29 days.
|
The study primary endpoint is the decrease of SOFA score by the end-of-treatment (EOT). This is defined as either a) at least 1.4 points decrease of mean SOFA score calculated between days 1 and EOT from SOFA score of day 0; OR b) at least 2 points decrease of SOFA at EOT from day 0. |
From enrollment to the end of treatment of the study drug for each of the study participants, ranging from 2 to 29 days.
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Il numero di dosi richieste in ciascun gruppo per ottenere la risposta del punteggio SOFA all'EOT.
Lasso di tempo: Dall'arruolamento alla fine del trattamento del farmaco in studio per ciascuno dei partecipanti allo studio, che varia da 2 a 29 giorni.
|
Dall'arruolamento alla fine del trattamento del farmaco in studio per ciascuno dei partecipanti allo studio, che varia da 2 a 29 giorni.
|
|
|
Mortalità a 28 giorni
Lasso di tempo: Dall'iscrizione a 28 giorni dopo l'iscrizione.
|
Dall'iscrizione a 28 giorni dopo l'iscrizione.
|
|
|
The rate of serious TEAEs and non-serious TEAEs
Lasso di tempo: From enrollment to the end of observation of each of the study participants, which is 120 days plus or minus 3 days, after each participant's enrollment.
|
Comparison of the rate of serious TEAEs and non-serious TEAEs between the three groups of treatment. |
From enrollment to the end of observation of each of the study participants, which is 120 days plus or minus 3 days, after each participant's enrollment.
|
|
The change of the SOFA score from day 0 until day 7
Lasso di tempo: From enrollment (day 0) to 8 days after enrollment (day 7).
|
Comparison of the change of the SOFA score from day 0 until day 7 |
From enrollment (day 0) to 8 days after enrollment (day 7).
|
|
The change of the SOFA score from 0 until day 28
Lasso di tempo: From enrollment to 28 days after enrollment.
|
Comparison of the change of the SOFA score from 0 until day 28 |
From enrollment to 28 days after enrollment.
|
|
The change of the SOFA score from 0 until EOT
Lasso di tempo: From enrollment to the end of treatment of the study drug for each of the study participants, ranging from 2 to 29 days.
|
Comparison of the change of the SOFA score from 0 until EOT |
From enrollment to the end of treatment of the study drug for each of the study participants, ranging from 2 to 29 days.
|
|
The pharmacokinetics of emapalumab
Lasso di tempo: From enrollment to the end of treatment of the study drug for each of the study participants, ranging from 2 to 29 days.
|
Comparison of the pharmacokinetics of emapalumab |
From enrollment to the end of treatment of the study drug for each of the study participants, ranging from 2 to 29 days.
|
|
The need to stop the study drug due to drop of the number of HLA-DR receptors on CD14-monocytes.
Lasso di tempo: From enrollment to the end of treatment of the study drug for each of the study participants, ranging from 2 to 29 days.
|
Comparison of the need to stop the study drug due to drop of the number of HLA-DR receptors on CD14-monocytes. |
From enrollment to the end of treatment of the study drug for each of the study participants, ranging from 2 to 29 days.
|
|
The circulating concentrations of IL-6, ferritin, IFNγ and CXCL9 over the days of treatment
Lasso di tempo: From enrollment to the end of treatment of the study drug for each of the study participants, ranging from 2 to 29 days.
|
Comparison of the circulating concentrations of IL-6, ferritin, IFNγ and CXCL9 over the days of treatment |
From enrollment to the end of treatment of the study drug for each of the study participants, ranging from 2 to 29 days.
|
Altre misure di risultato
Misura del risultato |
Lasso di tempo |
|---|---|
|
Confronto tra i tre gruppi di trattamento per il profilo proteomico rispetto al trattamento
Lasso di tempo: Dall'arruolamento alla fine del trattamento del farmaco in studio per ciascuno dei partecipanti allo studio, che varia da 2 a 29 giorni.
|
Dall'arruolamento alla fine del trattamento del farmaco in studio per ciascuno dei partecipanti allo studio, che varia da 2 a 29 giorni.
|
|
I confronti tra i tre gruppi di trattamento per la variazione del profilo trascrittomico rispetto al trattamento
Lasso di tempo: Dall'arruolamento alla fine del trattamento del farmaco in studio per ciascuno dei partecipanti allo studio, che varia da 2 a 29 giorni.
|
Dall'arruolamento alla fine del trattamento del farmaco in studio per ciascuno dei partecipanti allo studio, che varia da 2 a 29 giorni.
|
|
Le prestazioni diagnostiche del SepsiLoop point-of-care per SII rispetto al conteggio assoluto del recettore HLA-DR sui monociti CD45/CD14.
Lasso di tempo: Dall'arruolamento alla fine del trattamento del farmaco in studio per ciascuno dei partecipanti allo studio, che varia da 2 a 29 giorni.
|
Dall'arruolamento alla fine del trattamento del farmaco in studio per ciascuno dei partecipanti allo studio, che varia da 2 a 29 giorni.
|
|
I dati clinici e i livelli di biomarcatori al letto del paziente allo screening per il potenziale sviluppo di uno strumento diagnostico che classifichi la popolazione dello studio in IDS
Lasso di tempo: Dall'arruolamento alla fine del trattamento del farmaco in studio per ciascuno dei partecipanti allo studio, che varia da 2 a 29 giorni.
|
Dall'arruolamento alla fine del trattamento del farmaco in studio per ciascuno dei partecipanti allo studio, che varia da 2 a 29 giorni.
|
|
I livelli dei biomarcatori prognostici allo screening classificano la popolazione con sepsi in diversi sottogruppi
Lasso di tempo: Dall'arruolamento alla fine del trattamento del farmaco in studio per ciascuno dei partecipanti allo studio, che varia da 2 a 29 giorni.
|
Dall'arruolamento alla fine del trattamento del farmaco in studio per ciascuno dei partecipanti allo studio, che varia da 2 a 29 giorni.
|
Collaboratori e investigatori
Investigatori
- Cattedra di studio: Evangelos Giamarellos-Bourboulis, Hellenic Institute for the Studies of Sepsis
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- EMBRACE
- 2024-515255-38-00 (Ctis)
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .